Burning Rock Biotech Limited (NASDAQ: BNR) Expected to Post Earnings of $ 0.14 Per Share

0

Analysts expect Burning Rock Biotech Limited (NASDAQ: BNR) to report earnings of $ 0.14 per share for the current fiscal quarter, according to Zacks investment research. Zero analysts have released earnings estimates for Burning Rock Biotech. Burning Rock Biotech posted earnings per share of ($ 0.18) in the same quarter of last year, indicating a positive year-over-year growth rate of 177.8%. The company is expected to report its next results on Friday, November 19.

On average, analysts expect Burning Rock Biotech to report annual earnings of ($ 0.79) per share for the current year, with EPS estimates ranging from ($ 1.05) to (0 , $ 58). For the next fiscal year, analysts predict the company will post earnings of ($ 0.68) per share, with EPS estimates ranging from ($ 1.06) to ($ 0.32). Zacks earnings per share averages are an average based on a survey of seller-side research analysts who cover Burning Rock Biotech.

Burning Rock Biotech (NASDAQ: BNR) last reported its quarterly results on Monday, August 30. The company reported ($ 1.96) EPS for the quarter, missing analyst consensus estimates of ($ 0.14) by ($ 1.82). Burning Rock Biotech recorded a negative return on equity of 27.95% and a negative net margin of 134.93%.

BNR has been the subject of several recent analyst reports. CICC Research launched coverage on the shares of Burning Rock Biotech in a report published on Wednesday, July 14. They set an “outperformance” rating and a price target of $ 39.94 for the company. Zacks investment research downgraded Burning Rock Biotech’s shares from a “sell” rating to a “keep” rating in a report released on Monday, August 9.

(A d)

Members have been fortunate enough to over 10X their TOTAL PORTFOLIO by following our recommendations since May 2019 …

That’s why, for a week, you can join us to analyze the market LIVE …

And get all our market information and real-time trading recommendations …

Just RSVP here (no charge, no obligation).

BNR traded down $ 0.39 during Monday’s midday session, reaching $ 18.35. 7,962 shares of the company were traded, for an average volume of 343,868. The company has a market capitalization of $ 1.92 billion, a price / earnings ratio of -19.11 and a beta of -2.13 . Burning Rock Biotech has a one-year low of $ 17.56 and a one-year high of $ 39.75. The company has a 50-day simple moving average of $ 21.40 and a two-hundred-day simple moving average of $ 26.10.

Institutional investors and hedge funds have recently increased or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new position in shares of Burning Rock Biotech during the second quarter valued at $ 1,119,000. The New York State Common Retirement Fund purchased a new position in shares of Burning Rock Biotech during the first quarter for a value of $ 6,918,000. DE Shaw & Co. Inc. purchased a new position in shares of Burning Rock Biotech during the first quarter valued at $ 336,000. E Fund Management Hong Kong Co. Ltd. strengthened its position in shares of Burning Rock Biotech by 11.7% in the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 106,134 shares of the company valued at $ 3,127,000 after purchasing an additional 11,134 shares during the last quarter. Finally, Baillie Gifford & Co. strengthened its position in Burning Rock Biotech shares by 28.6% during the second quarter. Baillie Gifford & Co. now owns 8,462,422 shares of the company valued at $ 249,303,000 after purchasing an additional 1,880,294 shares in the last quarter. 25.72% of the shares are held by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech Limited mainly develops and supplies screening tests for cancer therapy in the People’s Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy screening tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and fluid biopsy samples.

Featured Article: Stock Symbols, CUSIP, and Other Stock Identifiers

Get a Free Copy of Zacks’ Research Report on Burning Rock Biotech (BNR)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Burning Rock Biotech now?

Before you consider Burning Rock Biotech, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Burning Rock Biotech was not on the list.

Although Burning Rock Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Source link

Leave A Reply

Your email address will not be published.